RETATRUTIDE
Retatrutide is a once-weekly investigational triple receptor agonist targeting GIP, GLP-1 and glucagon receptors. Unlike many compounds in the biohacking conversation, its weight-loss story is supported by large randomized trials. The biggest gap is no longer whether it can drive substantial weight loss—it is the leap from an investigational medicine in controlled trials to unapproved products sold outside that system.
Still investigational.
Multiple positive Phase 3 trials have been reported. Retatrutide is not FDA approved, and Lilly says it plans an FDA submission in Q1 2027.
Three signals.
One molecule.
Retatrutide (LY3437943) is an investigational peptide that activates three metabolic hormone receptors: GIP, GLP-1 and glucagon.
The first two targets are familiar from the incretin-drug story. Adding glucagon receptor agonism creates a distinct “triple agonist” approach intended to influence appetite, glucose regulation and energy metabolism through a single molecule.
The signal is real.
In the published Phase 2 obesity trial, 338 adults were randomized to retatrutide or placebo. At 48 weeks, mean weight change reached 24.2% in the 12 mg group versus 2.1% with placebo. The most common adverse events were gastrointestinal, and dose-dependent heart-rate increases peaked at 24 weeks before declining.
Since then, Lilly has reported positive topline Phase 3 results across five TRIUMPH studies. Its Q2 2026 presentation reported efficacy-estimand mean weight reductions of 28.3% at 80 weeks in TRIUMPH-1 and 28.7% at 68 weeks in TRIUMPH-4 at the 12 mg dose. TRIUMPH-2 and TRIUMPH-3 also reported substantial reductions in populations with type 2 diabetes or cardiovascular disease.
Where the data are strong—and where the story runs ahead.
Here, The Gap changes shape.
Exceptional attention
Online discussion centers on weight loss, appetite suppression, GI effects, fatigue, heart rate, sleep and comparisons with semaglutide and tirzepatide.
- Large weight-loss expectations
- Frequent comparison with approved incretin drugs
- Substantial interest in products sold before approval
- Anecdotes still cannot establish prevalence, safety or product authenticity
Substantial
Retatrutide has randomized controlled Phase 2 evidence and multiple reported positive Phase 3 trials in obesity and related cardiometabolic populations.
- Published randomized obesity Phase 2 trial
- Published randomized type 2 diabetes Phase 2 trial
- Multiple positive Phase 3 topline readouts
- Regulatory approval has not yet occurred
Weight loss: comparatively narrow—the clinical efficacy signal is strong. Unapproved access, product equivalence and broader claims: much wider. Evidence that Lilly’s investigational medicine works in controlled trials does not validate products marketed online as “retatrutide.”
Effective in trials does not mean approved—or risk-free.
Retatrutide has a much deeper human safety dataset than many compounds in the Peptide Index, but its benefit-risk profile is still undergoing development and regulatory evaluation.
In Phase 2 obesity research, gastrointestinal events were the most common adverse events and were dose-related, generally mild to moderate. Dose-dependent increases in heart rate were also observed. Phase 3 topline reports have described the most common adverse events as generally consistent with incretin-based therapies.
A fast-moving evidence story.
Research
TRIUMPH-2 and TRIUMPH-3 added two more positive Phase 3 readouts.
Lilly reported mean weight reductions up to 20.8% at 80 weeks in adults with obesity/overweight and type 2 diabetes and up to 22.6% in adults with severe obesity and established cardiovascular disease. Lilly also said it now has the clinical package to support planned global submissions.
Regulatory
FDA sharpened its warning around unapproved retatrutide.
FDA says retatrutide cannot be used in compounding under federal law and has warned companies involved in marketing, distributing or repackaging unapproved retatrutide.
Research
TRIUMPH-4 delivered the first successful Phase 3 readout.
In adults with obesity or overweight and knee osteoarthritis, Lilly reported mean weight loss up to 28.7% at 68 weeks along with substantial improvement in WOMAC knee-pain scores.
Show the receipts.
| Evidence | Design | What it adds | What it cannot prove |
|---|---|---|---|
| Obesity Phase 2 · PMID 37366315 | Randomized, double-blind, placebo-controlled · n=338 | Strong dose-dependent weight-loss efficacy signal through 48 weeks; characterizes common adverse events. | Does not establish long-term outcomes or regulatory approval. |
| Type 2 diabetes Phase 2 · PMID 37385280 | Randomized, double-blind, placebo + active-controlled · n=281 | Supports glycemic and weight effects in adults with type 2 diabetes. | Does not substitute for Phase 3 or regulatory review. |
| TRIUMPH-4 | Phase 3 · obesity/overweight + knee OA | Positive topline efficacy and safety readout; up to 28.7% mean weight loss reported at 68 weeks. | Topline company report is not the same as full peer-reviewed publication. |
| TRIUMPH-2 / TRIUMPH-3 | Phase 3 · metabolic/CV populations | Extends positive efficacy signal into type 2 diabetes and established cardiovascular disease populations. | Regulatory approval and full publication remain separate steps. |
| FDA unapproved GLP-1 guidance | Regulatory | Clarifies that retatrutide is unapproved and cannot legally be used in compounding. | Does not negate clinical-trial evidence for Lilly’s investigational product. |
Read deeper.
Follow the evidence.
Metabolic Health
Explore the biology and evidence behind compounds connected to obesity, glucose regulation and cardiometabolic health.
Tesamorelin
Compare two very different metabolic stories: triple-agonist obesity research versus an approved therapy with a specific indication.
Community Pulse
See what people are discussing without confusing online experience with clinical evidence.
BPC-157
Contrast retatrutide’s substantial clinical evidence with one of the widest evidence gaps in recovery culture.